OTU-15 Intermittent administration of PPI is not inferior to infusion following acute non-variceal upper gastrointestinal bleeding

Abstract

oesophagitis delayed treatment in 12.1% and hiatus hernia repair surgery was required in 1.3% of patients. Stricture rates were 5.4% requiring a median of 2 (IQR:6) dilatations and bleeding requiring hospital admission was 0.45%. RFA failed or was abandoned in 6.3% of patients. Metachronous lesions development during RFA treatment phase warranting further therapy in 14.9% patients: BO (2.7%) LGD (0.9%) HGD (5%) and IMC (6.3%). Metachronous lesions and BO developed after CRIM in 5% requiring further therapy and 0.9% developed invasive cancer. Median follow up post CRD/CRIM was 20.1 (±28.9) months. The survival rate over the 10-year study period was 94.6% with the majority of deaths due to unrelated disease. Conclusions This 10-year data demonstrates that RFA therapy is effective in achieving eradication of BO and dysplasia with a favourable safety profile.